Literature DB >> 8529795

Skeletal muscle kallikrein. Potential role in metabolic regulation.

R K Mayfield1, N Shimojo, A A Jaffa.   

Abstract

Skeletal muscle glucose metabolism appears to be regulated by locally derived factors as well as by systemically circulating hormones. Local factors may be particularly important during exercise, when substrate demand can increase rapidly. Numerous studies in perfused limbs suggest that the kallikrein-kinin system may participate in the regulation of substrate delivery and utilization by skeletal muscle. Evidence also suggests that kinins mediate the increase in insulin sensitivity after administration of converting enzyme inhibitors. Tissue kallikrein has been isolated and purified from rat skeletal muscles, and its level is highest in muscle with high oxidative activity. In other tissues, kallikrein synthesis is under the influence of insulin. It has not been possible to demonstrate effects of kallikrein or kinins on glucose metabolism in isolated skeletal muscle or cardiocytes. Therefore modulation of glucose metabolism by kallikrein or kinins may only be observed in intact perfused tissues or organs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8529795     DOI: 10.2337/diab.45.1.s20

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  4 in total

1.  Contraction-related factors affect the concentration of a kallidin-like peptide in rat muscle tissue.

Authors:  Fernando Boix; Laila Rosenborg; Ulrich Hilgenfeldt; Stein Knardahl
Journal:  J Physiol       Date:  2002-10-01       Impact factor: 5.182

2.  Gender-related associations of genetic polymorphisms of α-adrenergic receptors, endothelial nitric oxide synthase and bradykinin B2 receptor with treadmill exercise test responses.

Authors:  Rafael Amorim Belo Nunes; Lúcia Pereira Barroso; Alexandre da Costa Pereira; José Eduardo Krieger; Alfredo José Mansur
Journal:  Open Heart       Date:  2014-12-22

3.  Bdkrb2 gene -9/+9 polymorphism and swimming performance.

Authors:  A Grenda; A Leońska-Duniec; P Cięszczyk; P Zmijewski
Journal:  Biol Sport       Date:  2014-04-05       Impact factor: 2.806

4.  Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus.

Authors:  Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.